REG - IXICO plc - Result of AGM

IXICOAnnouncement

25/01/2024 16:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240125:nRSY9610Aa&default-theme=true

RNS Number : 9610A  IXICO plc  25 January 2024

 

25 January 2024

IXICO plc

("IXICO" or the "Company")

 

Results of AGM

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering insights in neuroscience announces that all resolutions put forward
to its Annual General Meeting held earlier today were duly passed and the
votes cast were as follows:

 

     RESOLUTION                                    VOTES       %       VOTES     %      VOTES       % ISC VOTED  VOTES

FOR
AGAINST
TOTAL
WITHHELD
 1   Reports and Accounts                          20,820,635  99.92%  16,913    0.08%  20,837,548  43.10        7,409

 2a  Re-election of Mark Warne                     20,811,026  99.87%  26,948    0.13%  20,837,974  43.10        6,983

 2b  Election of Dipti Amin                        20,814,152  99.92%  17,113    0.08%  20,831,265  43.08        13,692
 3   Appointment of Moore Kingston Smith Auditors  20,819,713  99.88%  24,122    0.12%  20,843,835  43.11        1,122
 4   Allotment of Securities                       20,819,913  99.89%  23,822    0.11%  20,843,735  43.11        1,222

 5   * Disapply Pre-Emption Provisions             20,800,863  99.80%  42,572    0.20%  20,843,435  43.11        1,522

* Special Resolution

Please note that a 'vote withheld' is not a vote under English Law and is not
counted in the calculation

of the proportion of the votes 'for' and 'against' a resolution.

 

For further information please contact:

 

 IXICO plc                                                  +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and   +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKPBPPBKDKDB